Aflibercept

EGFR Inhibitor

DB08885

Approved Indication

The opthalmic agent is used for the treatment of neovascular (wet) age-related mascular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for

3 Targets

0 Resistance Mutations

2 References

3D Structure No structure available

No co-crystal structure available

Protein Targets

PGF P49763 ✓ VEGFA P15692 ✓ VEGFB P49765 ✓

Mechanism of Action

Ablibercept is a recombinant fusion protein that acts as a decoy receptor for the ligands, vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). It prevents these ligands to binding to endothelial receptors, VEGFR-1 and VEGFR-2, to suppress neovascularization and decrease vascular permeability. This ultimately will slow vision loss or the progression of metastatic colorectal cancer.

Details

DrugBank ID DB08885 ↗

Approval Date 2011-11-21

Molecular Weight — g/mol

Drug Class EGFR Inhibitor

ATC Codes L01XX44, S01LA05

Synonyms VEGF Trap, VEGF Trap-Eye, Ziv-Aflibercept

ChEMBL CHEMBL1742982 ↗

Drug References (DrugBank)

PMID:23560774 PMID:23673444